» Articles » PMID: 15781660

Mimicry of a Cellular Low Energy Status Blocks Tumor Cell Anabolism and Suppresses the Malignant Phenotype

Abstract

Aggressive cancer cells typically show a high rate of energy-consuming anabolic processes driving the synthesis of lipids, proteins, and DNA. Here, we took advantage of the ability of the cell-permeable nucleoside 5-aminoimidazole-4-carboxamide (AICA) riboside to increase the intracellular levels of AICA ribotide, an AMP analogue, mimicking a low energy status of the cell. Treatment of cancer cells with AICA riboside impeded lipogenesis, decreased protein translation, and blocked DNA synthesis. Cells treated with AICA riboside stopped proliferating and lost their invasive properties and their ability to form colonies. When administered in vivo, AICA riboside attenuated the growth of MDA-MB-231 tumors in nude mice. These findings point toward a central tie between energy, anabolism, and cancer and suggest that the cellular energy sensing machinery in cancer cells is an exploitable target for cancer prevention and/or therapy.

Citing Articles

Effect of HPV Oncoprotein on Carbohydrate and Lipid Metabolism in Tumor Cells.

Chen B, Wang Y, Wu Y, Xu T Curr Cancer Drug Targets. 2024; 24(10):987-1004.

PMID: 38284713 DOI: 10.2174/0115680096266981231215111109.


Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers.

Yung M, Siu M, Ngan H, Chan D, Chan K Int J Mol Sci. 2022; 23(12).

PMID: 35743298 PMC: 9224484. DOI: 10.3390/ijms23126857.


Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity.

Yoon H, Shaw J, Haigis M, Greka A Mol Cell. 2021; 81(18):3708-3730.

PMID: 34547235 PMC: 8620413. DOI: 10.1016/j.molcel.2021.08.027.


AICAR, an AMP-Activated Protein Kinase Activator, Ameliorates Acute Pancreatitis-Associated Liver Injury Partially Through Nrf2-Mediated Antioxidant Effects and Inhibition of NLRP3 Inflammasome Activation.

Kong L, Zhang H, Lu C, Shi K, Huang H, Zheng Y Front Pharmacol. 2021; 12:724514.

PMID: 34531748 PMC: 8438129. DOI: 10.3389/fphar.2021.724514.


Pharmacological activation of pyruvate kinase M2 reprograms glycolysis leading to TXNIP depletion and AMPK activation in breast cancer cells.

Almouhanna F, Blagojevic B, Can S, Ghanem A, Wolfl S Cancer Metab. 2021; 9(1):5.

PMID: 33482908 PMC: 7821649. DOI: 10.1186/s40170-021-00239-8.